bebtelovimab   Click here for help

GtoPdb Ligand ID: 11921

Synonyms: LY-3853113 | LY-CoV-1404 | LY-CoV1404 | LY3853113
Compound class: Antibody
Comment: Bebtelovimab (LY3853113) is a SARS-CoV-2-neutralising monoclonal antibody that binds to the virus' spike surface glycoprotein [2]. It was reported to be effective against the delta and early omicron variants (B.1.617.2 and B.1.1.529 respectively). As of July 2022 bebtelovimab was the only available mAb to show preserved in vitro activity against the omicron BA.4 and BA.5 subvariants that were superceding previous omicron subvariants at that time [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Bebtelovimab is one of the mAbs being evaluated in clinical trial NCT04634409. It was granted FDA emergency use authorisation (EUA) on 11 February 2022. Its use is indicated for COVID-19 patients (with mild to moderate symptoms) who are at high risk of progressing to severe disease. The developers have not submitted bebtelovimab to regulatory agencies anywhere outside of the USA.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04634409 A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Phase 2 Interventional Eli Lilly and Company